Navigation Links
Investigational anti-restenosis drug pimecrolimus disappoints
Date:3/31/2008

o designed to a novel stent design featuring reservoirs that are filled individually with an active drug and resorbable polymer matrix. This design enables the stent to deliver more than one drug at a time from adjacent reservoirs. In the case of the GENESIS study, the SymBio stent was loaded with two medications that inhibit restenosis by two different pathways. In addition, the reservoirs limit the contact between the polymer and the artery wall.

For the study, Dr. Verheye and his colleagues enrolled 248 patients with single new coronary artery lesions, recruiting them from 18 medical centers in Europe and Israel. Patients were randomly assigned to stenting with the Corio stent, which delivers pimecrolimus; the SymBio stent, which delivers both pimecrolimus and paclitaxel; or the paclitaxel-coated CoStar stent. All of these stents are made with the reservoir design.

After nearly six months of follow-up, shrinkage of the arterial opening inside the stent (in-stent late loss) was greatest with the pimecrolimus-eluting Corio stent (1.40 mm), mid-range with the dual-drug SymBio stent (0.96 mm) and least with the paclitaxel-eluting CoStar stent (0.58 mm), but none of the differences between stents was statistically significant. Other angiographic findings followed the same pattern, including minimal lumen diameter, percent diameter stenosis and restenosis rateas did the findings of intravascular ultrasound at six months.

At six months, 39 percent of patients treated with the Corio stent experienced a major adverse cardiac event (MACE), including a 35 percent rate of repeat procedure in the target artery. With the SymBio stent, those rates were both 14.4 percent, and with the CoStar stent, they were both 2.0 percent. The difference in MACE rates between the CoStar stent and both of the pimecrolimus stents was highly statistically significant (p<0.0001). The rate of stent thrombosis at six months was 2.0 percent with the Corio stent, 1.0 per
'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Investigational drug tested for preventing muscle fiber death in muscular dystrophy
2. Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
3. New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets
4. UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
5. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
6. MetaCure(TM) Launches Investigational Study of Gastric Stimulator for Patients With Type 2 Diabetes Who are Overweight
7. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
10. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
11. Accentia announces investigational new drug application for Revimmune for refractory MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, ... skin from the upper arms to create a more toned, ... arm can become lax and may begin to sag, resulting ... the appearance of sagging upper arms, and seek treatment to ... is now offering brachioplasty to tighten and improve the ...
(Date:7/24/2014)... The Republic of Tea, leading purveyor of premium teas, is ... celebrate “The Hundred-Foot Journey,” a new major motion picture produced ... journey begins in the moment when you bravely drop what ... is far out of your comfort zone. It is a ... the course of your life for the better. , ...
(Date:7/24/2014)... Jose, California (PRWEB) July 24, 2014 ... for sugar alcohols, commonly known as food polyols, is ... confectionery sectors. Rising incidence of obesity, growing awareness ... aging population vulnerable to diabetes are some of the ... With growing number of scientific studies validating the health ...
(Date:7/24/2014)... 24, 2014 Freeslate, Inc ... solutions for biopharmaceutical development, today announced its feature ... Formulations” by Jim Kling. Topics of this ... formulations and how automation can help address many ... formulations have been a growing focus of pharmaceutical ...
(Date:7/24/2014)... Imbue Partners is pleased to announce ... the National Women Business Owners Corporation ( NWBOC ). ... , Located near Boston, MA, Imbue Partners is ... growth through strategic planning, organizational competencies, and enabling processes. ... through teams, tools, and technologies for all phases of ...
Breaking Medicine News(10 mins):Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of Diabetes and Obesity Drives the Global Sugar Alcohols Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 2Health News:Freeslate Featured in BioProcess International Article Discussing Challenges and Solutions to Highly Concentrated Protein Formulations 3Health News:Imbue Partners Certified as Woman-Owned Small Business 2
... the first long-term randomized trial of a chemopreventive agent for ... cancer in the drug-treated group may be attributable to shrinkage ... The study of the Prostate Cancer Prevention Trial, led by ... Gann, is published in the Sept. 12 issue of the ...
... Providers, SEATTLE, Sept. 12 , News Facts -- ... concerns and interests to the 2008 presidential candidates ... online physician community. -- The initiative is enabling U.S. licensed ... via individual web-based videos. Experts from a ...
... Wrinkles, HIGHLANDS, N.J., Sept. 12 Fifty really ... men in their 40s and 50s look better than,their ... can look incredibly sexy at any age. So ... keep the,attention of handsome himbos and beautiful babes? Biocap, ...
... Corporation,(Nasdaq: KNSY ) today announced that it will ... 30, 2007 at 7:00 A.M. Eastern Time on,Friday, October ... be hosting a teleconference,discussing the earnings results on Friday, ... participate in the teleconference call, dial 1-651-291-5254. The,teleconference call ...
... billion dollars. , But an unhealthy kidney costs moreabout ... associate professor in the division of nephrology and hypertension ... about $17 billion a year to care for patients ... currently over 320,000 people undergoing hemodialysis in the United ...
... Centers Head and Neck Cancer Center is teaming up ... cancer. The clinical alliance between Mount Sinai and ENT ... allergy and audiology practice in the tri-state area, together ... quality care, cancer screening and advanced surgical options for ...
Cached Medicine News:Health News:Shrinkage of prostate led to overestimation of cancer risk in trial 2Health News:U.S. Physicians Question Presidential Candidates 2Health News:Cougars Crave Biocap, The Haute Pepper Wrinkle Eraser 2Health News:Kensey Nash Corporation Announces its First Quarter 2008 Earnings Release Date and Teleconference 2Health News:Clinical trials present better alternatives for dialysis patients 2Health News:Mount Sinai & ENT and Allergy Associates, LLP affiliate to fight cancer 2
(Date:7/23/2014)... 2014  RT Oncology Services Corporation today announced that ... board of directors. Mr. Mundie is currently senior advisor ... on strategic projects within the company and on technology ... and strategy officer. Mike Martin ... "Craig is a visionary technology executive. His appointment is ...
(Date:7/23/2014)... BOHEMIA, N.Y. , July 23, 2014 /PRNewswire-iReach/ -- Top ... of GPM Pediatrics offers his feedback on article, which discusses ... Photo - http://photos.prnewswire.com/prnh/20140722/129440 According to ... of accidental injury and death among American children aged 1 ... inches of water." One expert in the article ...
(Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. Ltd., ... evaluate the use of udenafil to treat adolescents who ... heart defects. The clinical program will follow protocols developed ... Pediatric Heart Network (PHN), a multi-center clinical research network ... (NHLBI) of the National Institutes of Health (NIH). ...
Breaking Medicine Technology:Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3Premier Staten Island Pediatrician Dr. Michael Gabriel Comments On Article Discussing Pool Safety Tips for Parents 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... Medical, Inc. (OTCBB: AEMD) announced today that its wholly ... ability of its Enzyme Linked Lectin Specific Assay (ELLSA) ... immunodeficiency virus (HIV), tuberculosis (TB), and various forms of ... July 2010, ESI disclosed that it filed a patent ...
... WARSAW, Ind., April 12, 2011 Zimmer Holdings, Inc. (NYSE: ... quarter 2011 sales and earnings conference call will be broadcast ... 8:00 a.m. Eastern Time.  A news release detailing the quarterly ... the morning of the conference call. The ...
Cached Medicine Technology:Aethlon Medical Announces Multi-Target Exosome Assay Validation 2Aethlon Medical Announces Multi-Target Exosome Assay Validation 3Aethlon Medical Announces Multi-Target Exosome Assay Validation 4Aethlon Medical Announces Multi-Target Exosome Assay Validation 5Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: